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Summary
A high frequency of somatic mutations has been detected in stomach and esophageal cancers which makes them a 
possible suitable target for the application of immunotherapy. Contemporary immunotherapeutic approaches rely on 
monoclonal antibodies that inhibit immune checkpoints. The results of early clinical studies are promising, while only a few 
phase III studies have published their results so far. A particulary promising treatment strategy is the combination of check-
point inhibitors with other treatment modalities, such as chemotherapy, targeted therapy, radiotherapy or T cells agonists.
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NOVOSTI U IMUNOTERAPIJI TUMORA JEDNJAKA I ŽELUCA
Sažetak
U karcinoma jednjaka i želuca je nađena visoka učestalost somatskih mutacija što ih čini pogodnom metom za primje-
nu imunoterapije. Suvremeni pristupi u liječenju imunoterapijom temelje se na inhibiciji imunoloških kontrolnih točaka 
monoklonskim protutijelima. Rezultati kliničkih studija ranih faza su obećavajući dok je svega nekoliko studija faze III do 
sada objavilo svoje rezultate. Osobito je obećavajuća strategija liječenja kombinacijom inhibitora kontrolnih točaka s drugim 
modalitetima liječanja poput kemoterapije, ciljane terapije, radioterapije ili terapije agonistima T stanica.
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Introduction
Gastric cancer is the third leading cause of 
cancer-related death in the world with fi ve year 
survival rate of 29%, while esophageal cancer is 
the sixth leading cause of cancer-related death in 
the world with fi ve year survival rate of 18% (1,2). 
Such low and unsatisfactory survival rates are a 
consequence of a late diagnosis as well as low 
number of available eﬃ  cient therapies for treat-
ment of these diseases. The results of gene analy-
sis of these tumors gave the additional stimulus to 
explore new therapeutic potentials when four dif-
ferent subtypes of stomach adenocarcinoma as 
well as three subtypes of squamous cell esopha-
geal carcinoma have been recognized. (3,4). 
Esophageal adenocarcinoma and subtype of gas-
tric cancer characterized by chromosomal instabil-
ity seem to be the same disease at the molecular 
level (5). Despite these diﬀ erences, stomach and 
esophageal cancers share common feature which 
is a high prevalence of somatic mutations that 
makes them a suitable target for the application 
of immunotherapy (6). The use of immunothera-
py in other tumors with high prevalence of muta-
tions, such as melanoma and lung cancer, has 
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shown good eﬃ  cacy with a much longer response 
to treatment than the use of a standard chemo-
therapy.
Malignant tumors escape the host immune 
system by numerous mechanisms, including in-
creasing number of immunosuppressive cells in 
the tumor environment [regulatory T lympho-
cytes (Treg), myelod-derived suppressor cells 
(MDS)], cytokine levels [transforming growth fac-
tor β (TGF-β), interleukin 10 (IL-10), indoleamine 
2,3-deoxygenase (IDO)] and inhibitory signal 
pathways of immune checkpoints [cytotoxic T-
lymphocyte associated protein-4 (CTLA-4), pro-
grammed cell death protein-1 (PD-1), lymphocyte 
activation gene 3 (LAG3), T cell immunoglobulin 
and mucin domain-containing molecule-3 (TIM-
3)] (7). PD-1 inhibits T cells function by binding to 
its ligands PD-L1 and PD-L2 while CTLA-4 inhib-
its T cells by binding to CD80 and CD86. CTLA-4 
is important in early, and PD-1 and PD-L1 in late 
immune response. Current immunotherapeutic 
approaches rely on monoclonal antibodies that in-
hibit immune checkpoints. Numerous studies 
with immune checkpoint inhibitors are in prog-
ress (8). Gastric cancer associated with Epstein-
Barr virus (EBV) and gastric cancer subtype char-
acterized by microsatellite instability (MSI) are 
particularly suitable for the treatment with check-
point inhibitors due to increased expression of 
PD-L1 and PD-L2 (8).
Immunotherapy of esophageal 
and stomach cancer
After failure of standard therapy in patients 
with advanced or metastatic esophageal cancer, 
independent of the histological subtype, pembro-
lizumab (anti-PD-1) showed an objective response 
in 30.4% of patients and stabilization of the dis-
ease in additional 13% of patients (KEYNOTE-028, 
phase Ib) (9). The response was higher in adeno-
carcinoma (40%) than in squamous cell carcinoma 
(29.4%). Median duration of response was 40 
weeks, and one year progression free survival 
(PFS) was 21.7%.
Nivolumab (anti-PD-1) was tested (ONO-
4538/BMS-936558) in patients with advanced 
esophageal squamous cell carcinoma who failed 
standard treatments (10). In that phase II study 
nivolumab showed an objective response of 17.2% 
with median survival rate of 10.8 months. Addi-
tionally, 25% of patients had stable disease by in-
dependent review and 31.3% by investigator as-
sessment. The clinical benefi ts rates were 42% and 
53% respectively.
Based on promising results of phase II trials, 
two phase III trials of PD-1 blockade in esopha-
geal cancer are ongoing (8). KEYNOTE-181 exam-
ines pembrolizumab versus standard second line 
therapy (taxane or irinotecan) for advanced eso-
phageal and gastroesophageal junction (GEJ) can-
cers while the other (NCT02569242) compares 
nivolumab with taxane based second line chemo-
therapy for unresectable advanced and recurrent 
esophageal cancer. In addition, currently ongoing 
CheckMate-577 phase III study examines the adju-
vant application of nivolumab versus placebo in 
operated patients with esophageal cancer and GEJ 
cancer. Primary aims of the study are disease free 
survival (DFS) and overall survival (OS). In phase 
II study (NCT02520453) durvalumab, an anti-PD-
L1, has been compared with placebo in operated 
squamous cell carcinomas (8).
Pembrolizumab, nivolumab, avelumab and 
durvalumab demonstrated their eﬃ  cacy in the 
treatment of stomach and GEJ cancers in phase I 
and II clinical trials (11-14). The use of pembroli-
zumab in patients with PD-L1 positive gastric can-
cer (KEYNOTE 012 trial) showed an objective re-
sponse in 22% of patients by central assessment 
with a median duration of response of 40 weeks 
(15). Median survival rate was 11.4 months. The 
phase I/II CheckMate-032 trial demonstrated eﬃ  -
cacy of nivolumab in the treatment of advanced 
and metastatic gastric cancer (16). The objective 
response rate was 14%, irrespective of PD-L1 sta-
tus. The one-year survival rate was 36%. This trial 
also assessed the combination of nivolumab and 
ipilimumab (17). The best clinical activity and me-
dian OS were detected in the group treated with 
nivolumab 1 mg/kg and ipilimumab 3 mg/kg.
Results of the ONO-4538-12 (phase III) trial 
demonstrated that nivolumab signifi cantly re-
duced the risk of death by 37% [hazard ratio (HR) 
= 0.63; p < 0.0001] in patients with previously 
treated advanced gastric cancer refractory to stan-
dard therapy (18). The 12-month OS in the 
nivolumab group was 26.6% versus 10.9% in the 
placebo group. An objective response rate was 
11.2% in patients treated with nivolumab com-
pared to 0.0 % in patients treated with placebo. A 
median duration of response was 9.53 months.
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It should be emphasized that the most of 
phase III studies are still ongoing and their results 
are expected (8,11,14). These studies include KEY-
NOTE-061 trial of pembrolizumab versus pacli-
taxel after progression to platinum and fl uoropy-
rimidine based chemotherapy; KEYNOTE-062 
trial of pembrolizumab monotherapy versus com-
bination of pembrolizumab with cisplatin and 
5-fl uorouracil (5-FU) or cisplatin and 5-FU alone 
for the treatment-naïve disease; CheckMate-649 
trial of nivolumab plus ipilimumab verus oxalipa-
tin plus fl uoropyrimidine in patients with previ-
ously untreated advanced or metastatic gastric or 
GEJ cancers (19); JAVELIN Gastric 100 of avelum-
ab versus oxaliplatin-fl uropyrimidine doublet in 
the fi rst-line sett ing; and JAVELIN Gastric 300 of 
avelumab versus physician’s choice (irinotecan, 
paclitaxel or best supportive care) in the third-line 
sett ing.
Not only combinations of diﬀ erent check-
point inhibitors but also combinations of check-
point inhibitors with T cell agonists, chemothera-
py, radiotherapy or targeted therapy have been 
studied in esophageal and stomach cancers with 
the intention of achieving a bett er response (8). 
Radiotherapy not only has a profound eﬀ ect on 
the tumor immune microenvironment in the irra-
diated region, but can also induce anti-tumor im-
mune responses at distant sites (abscopal eﬀ ect) 
(20,21).
In addition, the application of immunothera-
py directed against tumor-related antigens such 
as melanoma 3 (MAGE-A3) and NY-ESO-1 anti-
gen has been investigated, as MAGE-A3 is found 
in 90% and NY-ESO-1 in 40-90% of esophageal 
cancers. Clinical studies with vaccines and adop-
tive cellular immunity are also ongoing (22).
IMAB362 is a chimeric monoclonal antibody 
against claudin 18.2, a tight junction protein that is 
expressed in about 70-80% of gastric cancers and 
also in some other tumors like bile duct and pan-
creatic cancers. IMAB362 mediates cell killing by 
antibody-dependent cell-mediated cytotoxicity 
(ADCC) and complement-dependent cytotoxicity 
(CDC) (23). In FAST phase II trial combination of 
IMAB362 and standard chemotherapy (epirubi-
cin, oxaliplatin, capecitabine; EOX) showed bett er 
median PFS (7.9 versus 4.8 months, HR = 0.47, p < 
0.0001), median OS (13.2 versus 8.4 months, HR = 
0.51; p = 0.0001) and higher objective response rate 
(39% versus 25%) than chemotherapy alone (24). 
To be eligible for the study at least 40% of patients’ 
tumors cells had to show an immunohistochemi-
cal expression of claudin 18.2 of at least 2+.
CONCLUSION
Intensive research and implementation of 
immunotherapy in recent years has led to new in-
sights and at the same time has opened up many 
issues. New immune-related response criteria (ir-
RCs) has been developed to comprehensively cap-
ture all response patt erns (25). A need for identifi -
cation of reliable predictive biomarkers has been 
recognized in order to reduce unnecessary expo-
sure to the side eﬀ ects in patients who would not 
respond to treatment as well as unnecessary costs 
(26). Data concerning PD-L1 expression as a po-
tential biomarker for therapy with checkpoint in-
hibitors in esophageal and gastric cancer are con-
tradictory and diﬀ er from study to study. This is 
due to the application of diﬀ erent antibodies and 
various criteria for evaluating expression results, 
applying fresh or archive tissue samples, deter-
mining expression either on tumor cells, or/and 
on tumor-infi ltrating immune cells. In addition to 
the need for standardization of these tests, it is 
also necessary to explore and understand the 
mechanism of the resistance to immunotherapy.
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